Sent from my BlackBerry® wireless handheld

From: Pharmacists_coffee <pharmacists_coffee@yahoo.com>

Sender: Pharmacists_coffee@yahoogroups.com

Date: Fri, 2 Sep 2011 14:11:28 +0200

ReplyTo: Pharmacists_coffee@yahoogroups.com

Cc: <pharmacists_coffee@yahoo.com>; <pharmacists_coffee@yahoogroups.com>

Subject: [PCM] Bayer Acquire Pathway Med. Technologies + Vacancies [1 Attachment]

[Attachment(s) from Pharmacists_coffee included below]

- To stop receiving newsletter, reply with "Stop"

- To subscribe to PCM newsletter click here

- To publish vacancy please click here

Home : Archive : Subscribe : Contact us : Upload CV : Invite friends : Publish Vacancy

Pharmacists_ coffee magazine
Electronic Edition
Edition No. 421, year 4
September 2, 2011
Today's edition sent to: 25,177 Arabian Pharmacists

Find Valuable attachment
"Time Management"
may find attachment at the end of e-mail

Today in Hot pharma news

Medicine of the week

Atorvastatin

Atorvastatin (INN) (pronounced /əˌtɔrvəˈstætən/), sold by Pfizer under the trade name Lipitor, is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.
Atorvastatin was first synthesized in 1985 by Bruce Roth while working at Parke-Davis Warner-Lambert Company (now Pfizer). With 2008 sales of US$12.4 billion, Lipitor was the top-selling branded pharmaceutical in the world.^[1] US patent protection is scheduled to expire in June 2011.^[2][3] However, Pfizer made an agreement with Ranbaxy Laboratories to delay the generic launch in the US until November 2011.^[1]

Indications:

Hypercholesterolemia[4] (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb) to reduce total cholesterol, LDL-C,[5] apo-B,[6] Triglycerides[7] levels, and CRP[8] as well as increase HDL levels.

Heterozygous familial hypercholesterolemia[4] in pediatric patients

Homozygous familial hypercholesterolemia[4][9]

Hypertriglyceridemia (Fredrickson Type IV)

Primary dysbetalipoproteinemia (Fredrickson Type III)

It has also been used in the treatment of combined hyperlipidemia.[10]

Secondary prophylaxis in patients with coronary heart disease and multiple risk factors for myocardial infarction, stroke, unstable angina,[11][12] and revascularization.[13][14]

Myocardial infarction and stroke prophylaxis in patients with type II diabetes.[15][16][17]

Concomitant therapy considerations

Atorvastatin may be used in combination with bile acid resins. It is not recommended to combine statin treatment with fibrates because of the increased risk of myopathy related adverse reactions.[18]Drug dose must be adjusted according to age of patient, and must be lowered in Hepatic insufficiency

Contraindications

Active liver disease: cholestasis, hepatic encephalopathy, hepatitis, and jaundice

Unexplained elevations in AST or ALT levels

Pregnancy

Breast-feeding

Precaution must be taken when treating with atorvastatin, because rarely it may lead to rhabdomyolysis,[19] it may be very serious leading to acute renal failure due to myoglobinuria. If rhabdomyolysis is suspected or diagnosed, atorvastatin therapy should be discontinued immediately.[20] Also Atorvastatin should be discontinued if a patient has markedly elevated CPK levels or if a myopathy is suspected or diagnosed. The likelihood of developing a myopathy is increased by the co-administration of cyclosporine, fibric acid derivatives, erythromycin, niacin, and azole antifungals.[18]

Atorvastatin is absolutely contraindicated in pregnancy, it is likely to cause harm to fetal development because of the importance of cholesterol and various products in the cholesterol biosynthesis pathway for fetal development, including steroid synthesis and cell membrane production. It is not recommended that nursing mothers take atorvastatin due to the possibility of adverse reactions in nursing infants, since experiments with rats indicate that atorvastatin is likely to be secreted into human milk.

KSA to KSA

+ Add a vacancy

Vacancy at Multinational Pharmaceutical Company In ABHA

A Multinational Pharmaceutical Company is Seeking for …

Medical Representative or Senior Medical Representative with the following criterion…

Age not more than 30, Male, and pharmacists only
Previous experience with at least 2 years as a medical representative
Previous work experience in ABHA, Khamis Mushiet, Najran, and Jazan
Transferable Iqama immediately after endorsement
Driving license
Submitted C.Vs should not more than one page in MS-Word format and with recent photo
Previous work experience and achievement should be validated and certified
Submit your C.V before September 10, 2011

Company has all rights to review and validate all data with full respect and confidentiality

send your C.V to the following e-mail:

jeff.george49@yahoo.com

jeff.george49@ yahoo.com

with subject of (ABHA Vacancy)

Friday, September 2, 2011

[PCM] Bayer Acquire Pathway Med. Technologies + Vacancies [1 Attachment]

Urgently we need :

Medical reps

Pharmacy in Nasr City

Pharmacy in Saqr Qourish

AstraZeneca announces top-line results from SATURN study

Bayer Healthcare to acquire Pathway Medical Technologies

Daiichi Sankyo & Ranbaxy Announce a New Social Contribution Initiative

€1 Million Awarded to Winning Projects

Additional Analyses from PLATO Presented at ESC Congress

U.S. Food And Drug Administration Approves Pfizer's XALKORI® (crizotinib)

Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes

Marketing-and-Selling-Marketing-Without-Advertising

No comments:

مصر اليوم

Slide Ads

منوعات عربية

Visitors

البيت بيتك

مكتبة الفيديو

Blog Archive

انشر هذا الموضوع على صفحتك